Genomic-scale prioritization of drug targets: The TDR Targets database

Fernán Agüero*, Bissan Al-Lazikani, Martin Aslett, Matthew Berriman, Frederick S. Buckner, Robert K. Campbell, Santiago Carmona, Ian M. Carruthers, A. W.Edith Chan, Feng Chen, Gregory J. Crowther, Maria A. Doyle, Christiane Hertz-Fowler, Andrew L. Hopkins, Gregg McAllister, Solomon Nwaka, John P. Overington, Arnab Pain, Gaia V. Paolini, Ursula PieperStuart A. Ralph, Aaron Riechers, David S. Roos, Andrej Sali, Dhanasekaran Shanmugam, Takashi Suzuki, Wesley C. Van Voorhis, Christophe L.M.J. Verlinde

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

252 Scopus citations

Abstract

The increasing availability of genomic data for pathogens that cause tropical diseases has created new opportunities for drug discovery and development. However, if the potential of such data is to be fully exploited, the data must be effectively integrated and be easy to interrogate. Here, we discuss the development of the TDR Targets database (http://tdrtargets.org), which encompasses extensive genetic, biochemical and pharmacological data related to tropical disease pathogens, as well as computationally predicted druggability for potential targets and compound desirability information. By allowing the integration and weighting of this information, this database aims to facilitate the identification and prioritization of candidate drug targets for pathogens.

Original languageEnglish (US)
Pages (from-to)900-907
Number of pages8
JournalNature Reviews Drug Discovery
Volume7
Issue number11
DOIs
StatePublished - 2008
Externally publishedYes

Bibliographical note

Funding Information:
The authors wish to acknowledge all of the investigators who provided the data in the TDR Targets database including those that participated in the survey on drug targets for Human African Trypanosomiasis (HAT survey) conducted during 2007. We would also like to acknowledge Brandeis University MS students P. Bais and B. Coflan for work on the association of targets with compounds; R. L. Stevens (Argonne National Laboratory) for providing data for gene essentiality in bacteria; K. Chaudhary and T. Carlow (New England BioLabs) for integrated C. elegans phenotype data; J. Sacchetini (Texas A&M) for information on known M. tuberculosis drug targets; and M. Schreiber (Novartis Institute for Tropical Diseases, Singapore) and J. Brown (GlaxoSmithKline) for input on integrating data on persistent expressed genes in dormant-stage M. tuberculosis infection. We would also like to acknowledge essential computational infrastructure and genome annotations made available through the OrthoMCL database (supported by the US National Institutes of Health; NIH); GeneDB (supported by the Wellcome Trust); Ensembl (supported by the European Bioinformatics Institute); and EuPathDB (supported by a Bioinformatics Resource Center contract from the US NIH/National Institute of Allergy and Infectious Diseases). The authors also gratefully acknowledge Pfizer Global Research and Development for sharing data related to druggability. This work was supported by grants from the United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Genomic-scale prioritization of drug targets: The TDR Targets database'. Together they form a unique fingerprint.

Cite this